|Bid||73.53 x 200|
|Ask||73.54 x 700|
|Day's Range||72.65 - 73.76|
|52 Week Range||63.76 - 82.10|
|PE Ratio (TTM)||7.76|
|Dividend & Yield||2.08 (2.88%)|
|1y Target Est||N/A|
Alkermes (ALKS) initiated the rolling submission of a New Drug Application (NDA) to the FDA for pipeline candidate ALKS 5461 for major depressive disorder.
Here is a look at four biotech stocks including Gilead (GILD) that topped estimates in Q2 and are witnessing upward estimate revisions for the current year.
Alexion Pharmaceuticals (ALXN) announced that the European Commission (EC) approved a label expansion of lead drug Soliris which should further boost sales.